Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, USA.
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, USA,
Cell Physiol Biochem. 2021 May 14;55(S5):1-14. doi: 10.33594/000000371.
Cannabidiol (CBD), the major non-intoxicating constituent of Cannabis sativa, has gained recent attention due to its putative therapeutic uses for a wide variety of diseases. CBD was discovered in the 1940s and its structure fully characterized in the 1960s. However, for many years most research efforts related to cannabis derived chemicals have focused on D9-tetrahydrocannabinol (THC). In contrast to THC, the lack of intoxicating psychoactivity associated with CBD highlights the potential of this cannabinoid for clinical drug development. This review details in vitro and in vivo studies of CBD related to the eye, the therapeutic potential of cannabidiol for various ocular conditions, and molecular targets and mechanisms for CBD-induced ocular effects. In addition, challenges of CBD applications for clinical ocular therapeutics and future directions are discussed.
大麻二酚（CBD）是大麻的主要非成瘾性成分，由于其对各种疾病的潜在治疗用途，近年来引起了广泛关注。CBD 于 20 世纪 40 年代被发现，其结构于 20 世纪 60 年代完全确定。然而，多年来，与大麻衍生化学物质相关的大多数研究工作都集中在 D9-四氢大麻酚（THC）上。与 THC 不同，CBD 缺乏致醉的精神活性，这突出了这种大麻素在临床药物开发方面的潜力。本综述详细介绍了 CBD 与眼睛相关的体外和体内研究，讨论了大麻二酚在各种眼部疾病中的治疗潜力，以及 CBD 诱导眼部效应的分子靶点和机制。此外，还讨论了 CBD 在临床眼科治疗中的应用挑战和未来方向。
